104 related articles for article (PubMed ID: 38777245)
1. Metabolomic biomarkers for benign conditions and malignant ovarian cancer: Advancing early diagnosis.
Zhang W; Lai Z; Liang X; Yuan Z; Yuan Y; Wang Z; Peng P; Xia L; Yang X; Li Z
Clin Chim Acta; 2024 Jun; 560():119734. PubMed ID: 38777245
[TBL] [Abstract][Full Text] [Related]
2. Identification of Potential Biomarkers and Metabolic Profiling of Serum in Ovarian Cancer Patients Using UPLC/Q-TOF MS.
Yang W; Mu T; Jiang J; Sun Q; Hou X; Sun Y; Zhong L; Wang C; Sun C
Cell Physiol Biochem; 2018; 51(3):1134-1148. PubMed ID: 30476914
[TBL] [Abstract][Full Text] [Related]
3. High resolution mass spectrometry coupled with multivariate data analysis revealing plasma lipidomic alteration in ovarian cancer in Asian women.
Zhang Y; Liu Y; Li L; Wei J; Xiong S; Zhao Z
Talanta; 2016 Apr; 150():88-96. PubMed ID: 26838385
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors.
Buas MF; Gu H; Djukovic D; Zhu J; Drescher CW; Urban N; Raftery D; Li CI
Gynecol Oncol; 2016 Jan; 140(1):138-44. PubMed ID: 26521694
[TBL] [Abstract][Full Text] [Related]
5. Serum Free Amino Acid Profiling in Differential Diagnosis of Ovarian Tumors-A Comparative Study with Review of the Literature.
Horala A; Plewa S; Derezinski P; Klupczynska A; Matysiak J; Nowak-Markwitz E; Kokot ZJ
Int J Environ Res Public Health; 2021 Feb; 18(4):. PubMed ID: 33672144
[TBL] [Abstract][Full Text] [Related]
6. Highly-accurate metabolomic detection of early-stage ovarian cancer.
Gaul DA; Mezencev R; Long TQ; Jones CM; Benigno BB; Gray A; Fernández FM; McDonald JF
Sci Rep; 2015 Nov; 5():16351. PubMed ID: 26573008
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Value of Serum Angiogenesis Markers in Ovarian Cancer Using Multiplex Immunoassay.
Horala A; Swiatly A; Matysiak J; Banach P; Nowak-Markwitz E; Kokot ZJ
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28075407
[TBL] [Abstract][Full Text] [Related]
9. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
10. Performance of IOTA ADNEX model in evaluating adnexal masses in a gynecological oncology center in China.
Chen H; Qian L; Jiang M; Du Q; Yuan F; Feng W
Ultrasound Obstet Gynecol; 2019 Dec; 54(6):815-822. PubMed ID: 31152572
[TBL] [Abstract][Full Text] [Related]
11. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer: A Meta-analysis.
Dayyani F; Uhlig S; Colson B; Simon K; Rolny V; Morgenstern D; Schlumbrecht M
Int J Gynecol Cancer; 2016 Nov; 26(9):1586-1593. PubMed ID: 27540691
[TBL] [Abstract][Full Text] [Related]
13. LC-MS/MS platform-based serum untargeted screening reveals the diagnostic biomarker panel and molecular mechanism of breast cancer.
Gong S; Wang Q; Huang J; Huang R; Chen S; Cheng X; Liu L; Dai X; Zhong Y; Fan C; Liao Z
Methods; 2024 Feb; 222():100-111. PubMed ID: 38228196
[TBL] [Abstract][Full Text] [Related]
14. Assessment of diagnostic utility of multivariate diagnostic models in differential diagnosis of ovarian tumors.
Horała A; Swiatly A; Lorek J; Kokot ZJ; Matysiak J; Nowak-Markwitz E
Ginekol Pol; 2018; 89(10):568-572. PubMed ID: 30393846
[TBL] [Abstract][Full Text] [Related]
15. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.
Fawzy A; Mohamed MR; Ali MA; Abd El-Magied MH; Helal AM
Asian Pac J Cancer Prev; 2016; 17(1):323-33. PubMed ID: 26838232
[TBL] [Abstract][Full Text] [Related]
16. Wide spectrum targeted metabolomics identifies potential ovarian cancer biomarkers.
Plewa S; Horała A; Dereziński P; Nowak-Markwitz E; Matysiak J; Kokot ZJ
Life Sci; 2019 Apr; 222():235-244. PubMed ID: 30853626
[TBL] [Abstract][Full Text] [Related]
17. Using a panel of multiple tumor-associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer.
Wang P; Qin J; Ye H; Li L; Wang X; Zhang J
J Cell Biochem; 2019 Mar; 120(3):3091-3100. PubMed ID: 30484895
[TBL] [Abstract][Full Text] [Related]
18. Performance of a multianalyte test as an aid for the diagnosis of ovarian cancer in symptomatic women.
Autelitano DJ; Raineri L; Knight K; Bannister K; Rice GE
J Transl Med; 2012 Mar; 10():45. PubMed ID: 22410202
[TBL] [Abstract][Full Text] [Related]
19. Biomarker-based early detection of epithelial ovarian cancer based on a five-protein signature in patient's plasma - a prospective trial.
Hasenburg A; Eichkorn D; Vosshagen F; Obermayr E; Geroldinger A; Zeillinger R; Bossart M
BMC Cancer; 2021 Sep; 21(1):1037. PubMed ID: 34530759
[TBL] [Abstract][Full Text] [Related]
20. Approaches to the detection of ovarian cancer.
Høgdall E
Scand J Clin Lab Invest Suppl; 2016; 245():S49-53. PubMed ID: 27435369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
